FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen

Image Source: Zacks Investment Research Olezarsen is one of Ionis' wholly-owned pipeline candidates, which it intends to launch independently in the United States. The drug's commercial launch is part of management's broad strategy to deliver a steady flow of wholly-owned medicines to patients. If approved, the drug will not only be Ionis' first independent product launch but also the first FDA-approved treatment for FCS. Last month, Ionis reported positive data from two phase III studies — OASIS-HAE and OA ...